HAEMACURE CORPORATION.

Making strides in biosurgical technology.

When Marc Paquin formed Haemacure Corporation more than 10 years ago, it was his goal to one day become an international leader in the biosurgical wound-care industry. In 1999, that goal became a reality.

Haemacure Corporation produces [Hemaseel.sup.TM] APR, a fibrin sealant that forms blood clots within seconds. Hemaseel APR consists of two blood proteins, fibrinogen and thrombin, which form a mesh-like structure when mixed. Used after surgery, the sealant stops bleeding, reduces the risk of complications and immunological infections, and speeds healing. Having received FDA approval in May 1998, Hemaseel APR was the first of two commercially available fibrin sealants in the United States. It replaces the homemade fibrin glues many hospitals use and offers a superior level of viral safety and consistency.

The sealant is already widely used among the 800,000 cardiovascular surgeries performed each year. Paquin, Haemacure's president and CEO, believes the product has many additional applications. "Multiple hospitals and surgeons have used Hemaseel APR for trauma surgery, cardiopulmonary surgery and other indications," says Paquin.

Since the product's introduction, Haemacure's sales have increased 30-percent per quarter, with sales of $1.5 million last quarter. Paquin expects Haemacure's sales to continue their dramatic rise, and he has recently increased his national sales staff from 15 to 90 representatives. By 2002, he hopes to bring a new product, Hemaseel HMN, to the market. Currently in clinical trials in the U.S., Hemaseel HMN uses a new sealing technology that will be ideal for non-cardio-based surgeries.

The Swiss Red Cross believes so strongly in Haemacure's products that it has invested $15 million in the company, becoming Haemacure's largest shareholder. Paquin also plans to make an announcement soon regarding a new manufacturing partner for Haemacure. It's a very exciting partnership," according to Paquin, because the organization has an existing plasma fractionation facility in Europe at a cost of more than $200 million. This facility separates plasma proteins necessary for the production of Hemaseel APR and HMN.

With such exciting announcements and advances, Paquin is understandably proud of the achievements made by Haemacure Corporation in 1999. Traded publicly on the Toronto and Montreal Canadian stock exchanges under the symbol HAE and listed in the U.S. in Standard & Poor's Stock Reports, Haemacure is a company to watch in the new millennium.